Acadia Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Roth Capital
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)‘s stock had its “neutral” rating restated by investment analysts at Roth Capital in a research report issued on Wednesday.
Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Acadia Pharmaceuticals in a research note on Monday, August 8th. Vetr cut Acadia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $41.00 price objective on the stock. in a research note on Tuesday, July 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price objective on shares of Acadia Pharmaceuticals in a research note on Tuesday, July 26th. Jefferies Group reaffirmed a “buy” rating on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Finally, JMP Securities reissued a “buy” rating and issued a $45.00 target price on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Acadia Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $45.70.
Acadia Pharmaceuticals (NASDAQ:ACAD) opened at 24.33 on Wednesday. The firm’s market capitalization is $2.77 billion. The company’s 50-day moving average price is $31.04 and its 200-day moving average price is $33.12. Acadia Pharmaceuticals has a 1-year low of $16.64 and a 1-year high of $43.30.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/acadia-pharmaceuticals-inc-acad-stock-rating-reaffirmed-by-roth-capital.html
Acadia Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by $0.14. Acadia Pharmaceuticals had a negative net margin of 131,066.23% and a negative return on equity of 64.25%. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.71 million. During the same period last year, the business posted ($0.39) earnings per share. The firm’s quarterly revenue was up 96900.0% compared to the same quarter last year. Equities research analysts expect that Acadia Pharmaceuticals will post ($2.14) earnings per share for the current fiscal year.
In other Acadia Pharmaceuticals news, Director Edmund Harrigan bought 1,000 shares of the stock in a transaction dated Tuesday, August 16th. The stock was purchased at an average cost of $32.97 per share, for a total transaction of $32,970.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $32,970. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker bought 1,303,030 shares of the stock in a transaction dated Wednesday, August 10th. The shares were acquired at an average price of $33.00 per share, with a total value of $42,999,990.00. The disclosure for this purchase can be found here. Company insiders own 21.65% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Acadia Pharmaceuticals by 23.0% in the first quarter. Geode Capital Management LLC now owns 675,017 shares of the biopharmaceutical company’s stock valued at $18,873,000 after buying an additional 126,169 shares during the last quarter. Pictet Asset Management Ltd. raised its position in Acadia Pharmaceuticals by 30.2% in the first quarter. Pictet Asset Management Ltd. now owns 311,216 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 72,189 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Acadia Pharmaceuticals by 5.1% in the first quarter. UBS Asset Management Americas Inc. now owns 805,484 shares of the biopharmaceutical company’s stock valued at $22,522,000 after buying an additional 39,224 shares during the last quarter. State Street Corp raised its position in Acadia Pharmaceuticals by 42.1% in the first quarter. State Street Corp now owns 3,364,426 shares of the biopharmaceutical company’s stock valued at $94,072,000 after buying an additional 997,205 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Acadia Pharmaceuticals during the first quarter valued at about $14,399,000. Hedge funds and other institutional investors own 92.07% of the company’s stock.
Acadia Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings for Acadia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.